TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04005131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot and tDCS on-line after sham tDCS
Description: Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 times a week for 5 weeks
Study: NCT03632850

Intervention type: OTHER
Intervention: web-based interactive tool
Description: an online tool to assist users in decision-making in choice of treatment for advanced cancer

Intervention type: OTHER
Intervention: web-based interactive tool
Description: an online tool to assist users in decision-making in choice of treatment for advanced cancer

Intervention type: OTHER
Intervention: web-based interactive tool
Description: an online tool to assist users in decision-making in choice of treatment for advanced cancer

Intervention type: OTHER
Intervention: web-based interactive tool
Description: an online tool to assist users in decision-making in choice of treatment for advanced cancer
Study: NCT04197596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BK CTL
Description: Patient with refractory BK infection and a HLA Matched Related Donors: BK specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~Patients with refractory BK virus and a HLA Mismatched Related Donors: BK specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg).
Study: NCT03568227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The hypnosis intervention consists of two elements: A hypnotic induction and a hypnotic deepening. The induction aims at guiding the participant into the first hypnotic state (state 1). The participants will remain in this state for 10 minutes, the duration of the fMRI-scan. The hypnotic deepening guides the participants into a very deep hypnotic state (state 2). Participants also remain in this state for 10 minutes, during which their brain activity is measured using fMRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: The control intervention consists of texts corresponding to the induction and deepening of the hypnosis intervention. They are matched in duration and consist of textually matched excerpts from www.wikipedia.org. Control induction will be presented, resulting in the control state 1 (10 min). Then the control deepening will be performed, leading to the control state 2 (10 minutes). During both control states the brain activity will be recorded using fMRI.
Study: NCT02015910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimick Sitagliptin 100mg pill.
Study: NCT02550639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BIOMARKER- elispot test
Description: ELISPOT TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BIOMARKER- elispot test
Description: ELISPOT TEST

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BIOMARKER- elispot test
Description: ELISPOT TEST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BIOMARKER- elispot test
Description: ELISPOT TEST
Study: NCT00209612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Day1,15 X mg/m2, IV (in the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campt, Topotesin
Description: Day1,15 Y mg/m2, IV (in the vein)
Study: NCT05932823

Intervention type: OTHER
Intervention: Laminary airflow
Description: A ventilation system that reduces the number of bacteria in the air compared to conventional ventilation.
Study: NCT02808598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Cancer Clinical Trials Education Program
Description: The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Breast Cancer Clinical Trials Education Program
Description: The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.
Study: NCT03029169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone i.v.
Description: Treatment
Study: NCT04448756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants received M5049 50 milligram (mg) orally twice daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants received M5049 100 mg orally twice daily for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo tablets matched to M5049 daily for 14 days.
Study: NCT01353456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patient will receive a loading dose of 1μg/kg (0.25ml/kg) intravenous dexmedetomidine over 10 minutes before induction, and then followed by continuous infusion at a rate of 0.5μg/kg/h (0.125ml/kg/h) until wound closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Same volume as dexmedetomidine given
Study: NCT03188354

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: PET scan with 18F-FDG as a tracer, taken both for primary staging and therapy assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine
Description: PET scan with 18F-fluciclovine as a tracer, taken both for primary staging and response to therapy assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standard MRI
Description: clinical routine MRI examination, both for primary staging and response to therapy assessment.
Study: NCT04260802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC-001
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: OC-001 in Combination with Avelumab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: OC-001 in Combination with Avelumab
Description: Administered IV.
Study: NCT02710773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backward Walking Treadmill Training
Description: The intervention will consist of 5 minutes of forward walking (warm-up phase), 10 minutes of backward walking (intervention phase) and 5 minutes of forward walking (cool-down phase). The session will be performed on a treadmill device. The backward training speed will be increase consecutively: during the week 1, the intervention will be performed at 0,8 km/h; during the week 2 the speed will be 1,0 km/h; finally, during the week 3 the speed will be increased till 1,2 km/h.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Training
Description: The intervention will consist of 20 minutes of forward walking on a treadmill device.
Study: NCT03740451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active mobilization of soft tissues
Description: This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive mobilization
Description: This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
Study: NCT00437229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) Oral Tablets
Description: Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) Oral Tablets
Description: Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone will be available as 4 mg tablets for oral administration and injection for IV administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone will be available as 4 mg tablets for oral administration and injection for IV administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron for oral use will be available as 8 mg tablets to be taken with 240 milliliters (mL) of water on an empty stomach. For IV use, ondansetron 32 mg will be infused intravenously over a period of 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron for oral use will be available as 8 mg tablets to be taken with 240 milliliters (mL) of water on an empty stomach. For IV use, ondansetron 32 mg will be infused intravenously over a period of 15 minutes.
Study: NCT01662765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: modified umbilectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative
Description: this treatment will include conservative procedures under local anesthesia for patient comfort.
Study: NCT01986426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315 consecutive lesions
Description: Dose escalation:~Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315
Description: Dose escalation:~Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315 + ipilimumab
Description: Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315 + pembrolizumab
Description: Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab
Study: NCT02129699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).

Intervention type: OTHER
Group type: OTHER
Intervention: None, standard chemotherapy only
Description: Possible standard chemotherapies (3 weeks cycles, duration: 4 - 6 cycles):~Cisplatin 75 mg/m2 as an infusion on day 1 Gemcitabine 1250 mg/m2 as an infusion days 1 and 8 or Carboplatin AUC 5 as an infusion on day 1 Gemcitabine 1000 mg/m2 as an infusion days 1 and 8 or Cisplatin 75 mg/m2 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1 or Carboplatin AUC 5 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1
Study: NCT06520917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Locator-Positioner (LOPO) Guide Device
Description: Patients underwent temporomandibular joint arthroscopy with the aid of the LOPO guide device
Study: NCT02772458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dodecanoate acid and saline
Description: Test drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dodecanoate acid and saline
Description: Test drink
Study: NCT03957577

Intervention type: OTHER
Intervention: Prospective observational cohort study
Description: Prospective observational cohort study
Study: NCT01349335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: tablet, 15 mg, Qd, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: tablet, 30 mg, Qd, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: tablet, 30 mg, Qd, 7days.
Study: NCT02150330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone (DHEAS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone (DHEAS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone (DHEAS)
Study: NCT03342248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: access to the social network
Description: The development of a social network via a digital platform for carers of patients suffering from severe mental illness and study of the impact of its use on the health status of caregivers
Study: NCT04597814

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT00160381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10mg Tablet, oral Daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 25 mg Tablet, oral Daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral Daily for 12 months
Study: NCT00315939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)
Description: Integrated Biobehavioral Monitoring \& Feedback-1 (IBMF-1): a hand-held computer (HHC) was given to the subjects, programmed to estimate HbA1c, risk for hypoglycemia (Low BG Index), and glucose variability (Average Daily Risk Range) using previously published algorithms. The subjects were asked to carry the HHC and enter all their self-monitored blood glucose (SMBG) readings. The estimates of HbA1c were updated weekly, and the estimates of risk for hypoglycemia and glucose variability were updated at each SMBG entry. Detailed instructions were provided on the meaning of these different types of glucose feedback; the study staff was available to answer any questions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)
Description: Integrated Biobehavioral Monitoring \& Feedback-1 (IBMF-1): a hand-held computer (HHC) was given to the subjects, programmed to estimate HbA1c, risk for hypoglycemia (Low BG Index), and glucose variability (Average Daily Risk Range) using previously published algorithms. The subjects were asked to carry the HHC and enter all their self-monitored blood glucose (SMBG) readings. The estimates of HbA1c were updated weekly, and the estimates of risk for hypoglycemia and glucose variability were updated at each SMBG entry. Detailed instructions were provided on the meaning of these different types of glucose feedback; the study staff was available to answer any questions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)
Description: Integrated Biobehavioral Monitoring \& Feedback-2 (IMBF-2) retains IMBF-1, but the HHC asked subjects to provide symptom ratings when blood glucose (BG) was low and at an equal number of matching euglycemic readings. From these data, the HHC estimated a set of potentially significant symptoms of hypoglycemia for each individual, using an iterative algorithm following a previously published symptom significance estimation procedure. The patient manual for the HHC program is provided in supplementary data of published manuscript.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)
Description: Integrated Biobehavioral Monitoring \& Feedback-2 (IMBF-2) retains IMBF-1, but the HHC asked subjects to provide symptom ratings when blood glucose (BG) was low and at an equal number of matching euglycemic readings. From these data, the HHC estimated a set of potentially significant symptoms of hypoglycemia for each individual, using an iterative algorithm following a previously published symptom significance estimation procedure. The patient manual for the HHC program is provided in supplementary data of published manuscript.
Study: NCT03312699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® quadrivalent
Description: IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose
Description: High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluad
Description: Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaqta
Description: Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaqta
Description: Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhim Vi
Description: Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhim Vi
Description: Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vivotif
Description: One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm \[temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)\] drink on alternate days, e.g., days 1, 3, 5 and 7.
Study: NCT04112654

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pressure laparoscopy
Description: Conventional pressure laparoscopy using conventional insufflator AirSeal®

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low pressure laparoscopy
Description: Low pressure laparoscopy using pressure-controlled insufflator AirSeal®
Study: NCT04244487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation
Description: The modified procedure was implemented in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, divide the left lateral surface of the distal esophagus; (3) divide the posterior surface of the distal esophagus; (4) divide the anterior surface of the distal esophagus; (5) divide the lesser omental sac via the bottom right crural diaphragm; (6) transect en bloc the left gastric artery and vein and posterior gastric veins using a linear laparoscopic vascular stapler; (7) find the right crural diaphragm by dividing a small portion of the hepatogastric ligament at the left lateral esophagogastric junction; and (8) via the surface of the right crural diaphragm, divide the right lateral surface of the distal esophagus.~After the procedure of laparoscopic azygoportal disconnection, intraoperative endoscopic variceal ligation was made if the diameter of the esophageal varices was \>5 mm.
Study: NCT04342832

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon ablation
Description: If a patient is randomized to early invasive treatment, the ablation is performed within 3 months by an experienced cardiac electrophysiologist using CE-certified equipment. Via the femoral vein a guiding catheter is advanced through the inferior vena cava to the right atrium and into the left atrium via transseptal puncture. Then, the cryoballoon is advanced, inflated, and placed against one of the four PVs. PV occlusion is assessed by selective contrast injection. When adequate PV antral seal is confirmed, ablation of the tissue in contact with the balloon is performed using pressurized liquid nitrous oxide. The cold inflated balloon thus creates circular lesions around the PV. The balloon and tissue interface are then allowed to reach normal temperatures. Depending on local practice, the freeze-thaw cycle may be repeated twice. Electrical isolation is assessed and when it is confirmed, the next PV is treated in the same way. The procedure ends when all PV's are isolated.
Study: NCT02847741

Intervention type: OTHER
Group type: OTHER
Intervention: patient's routine care
Description: Interview by psychiatrists, questionnaires, blood analysis
Study: NCT00301522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation
Description: Paclitaxel-Eluting Coronary Stent, Slow-Formulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Express2
Description: Coronary Stent System
Study: NCT03912194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral withdrawal regulation strategies
Description: Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-behavioral withdrawal regulation strategies
Description: Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist
Study: NCT00231153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan 1% gel
Description: Patients randomized to omiganan group will receive an application of omiganan gel around the catheter insertion site following catheter insertion. Every 3 days the dressing will be changed and patients will receive a new application of Omiganan 1% gel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine 10%
Description: All CVC sites will be disinfected using a 10% povidone-iodine scrub for a minimum of 2 minutes prior to catheter insertion. Patients randomized to the povidone-iodine group will receive no further antiseptic treatment after catheter insertion until dressing changes. Every three days the dressing will be changed and the catheter site will be sterilized with povidone-iodine.